• [Show abstract] [Hide abstract]
    ABSTRACT: Autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, have a strong association with an increased risk of atherosclerotic cardiovascular diseases (ASCVD), particularly ischemic heart disease (IHD). A majority of the autoimmune conditions occur predominantly in women, and as women continue to experience a higher cardiovascular mortality compared to men, this potential added risk factor must be recognized. Inflammation and immune mechanisms have been shown to be an underlying mechanism for the development of atherosclerosis, thus sharing a common mechanism with rheumatologic conditions. There is an under recognition, in both patient and physician, of the increased cardiovascular (CV) risk within the autoimmune population, with present CV risk profile algorithms performing poorly in these patients. Traditional risk factors play a role in the development of IHD in the autoimmune patient, but their overall significance is unclear and does not fully explain the elevated CV risk. The role of inflammation and risk factors in autoimmune conditions, and their link to the elevated CV risk will be explored within this article.
    Current Atherosclerosis Reports 04/2015; 17(4):497. DOI:10.1007/s11883-015-0497-6 · 3.06 Impact Factor
  • Food science and biotechnology 08/2014; 23(4):1267-1272. DOI:10.1007/s10068-014-0174-5 · 0.66 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Phosphorylcholine is one of the major epitopes of oxidised low density lipoprotein. Low levels of IgM antibodies against phosphorylcholine (anti-PC) are associated with development of myocardial infarction and stroke. It has been shown that patients with Alzheimer¿s disease and other dementias have significantly lower serum anti-PC levels compared to controls, suggesting that low levels of atheroprotective anti-PC may play a role in AD and dementia.Methods We quantified levels of anti-PC levels using an ELISA in plasma from 176 controls, 125 patients with Alzheimer¿s disease, 19 patients with vascular dementia and 63 patients with other dementias.ResultsWe observed similar plasma anti-PC levels in controls, patients with Alzheimer¿s disease, and other dementias.Conclusions Our data suggests that anti-PC is not useful as a biomarker for Alzheimer¿s disease.
    BMC Neurology 02/2015; 15(1):8. DOI:10.1186/s12883-015-0260-1 · 2.49 Impact Factor

Full-text (2 Sources)

Available from
Jul 15, 2014